医疗设备维护管理信息系统的开发与研究

本文基于C Builder和SQLServer开发平台,介绍了设备维护管理信息系统的开发设计,实施及应用拓展,为医院对医疗设备的维护管理及科学决策作出积极探索。     

医院网上预约挂号系统

目前，门诊一直是困扰医院提高服务质量的一个复杂环节，特别是医疗水平高、门诊量大的医院，门诊质量难以提高。此外，病人到医院就诊前对医院的相关信息了解不多，对所要挂的专科医生的情况又不太了解，具有较大的盲目性。随着互联网络的迅猛发展．我院的网站利用ASP技术以及ActiveX组件实现了网上预约挂号功能，用户可在网上通过浏览器很方便地查看医院介绍、专家、专科等具体的信息，通过这些措施可以正确引导病人选择所需的专家、专科或针对性强的医疗服务，提高医院门诊服务质量，为广大群众的就医提供了方便，取得良好的社会效益和经济效益。     

科室调整时"军卫一号"的数据转换

科室调整时。病人要随之分配到新的科室，病人的各种医疗数据要转换为新科室的数据。利用结构化查询语言，根据病人的调整情况，实施数据调整。这种数据转换方法，不但适用于新、老药品结构的“军卫一号”，而且其基本原理也适用于科室分开而护理单元不分开的情况。     

A Note on the Asymptotic Properties of Affected-sib-pair Linkage Tests

This article concerns the asymptotic properties of linkage tests for affected‐sib‐pair data under the null hypothesis of no linkage. We consider a popular single‐locus analysis model where the unknown parameters are the disease allele frequency, the three penetrances for the three genotypes at the disease locus, and the recombination fraction between the marker locus and the disease locus. These parameters are completely confounded under the null hypothesis of no linkage. We show that 1) If the total variance of the trait (i.e., the additive variance plus the dominance variance) is “separated” from 0, then the likelihood ratio statistic has an asymptotic 0.5χ²₀+ 0.5χ²₁ distribution; 2) If the prevalence of the trait is “separated” from 0 and the recombination fraction is fixed at 0, then the likelihood ratio statistic has an asymptotic distribution which is a mixture of χ²₀, χ²₁ and χ²₂ . The implications of these results are discussed.     

浅谈网站建设中的一些细节问题

结合“作业管理系统”实例,阐述了网站建设中细节上常见的技术问题,引出这些问题涉及的基本概念及给出适用的处理方法,并做出相应的结论。     

基于网络的在线调查统计系统的分析与实现

阐述了在线调查统计系统的体系结构和具体实现方法,解决了动态选择调查主题和以图表形式显示调查结果等难点并给出在线调查误差控制的方法。     

LINQ在医院信息系统的应用

LINQ是一种新的数据访问技术，提供了一种用于在不同类型的数据源中查询和更新数据的统一编程模型，提高了编程的效率，降低了访问数据的复杂度。介绍了LINQ的特点、作用及其在开发医院信息系统中的具体应用。     

The ALK inhibitor ASP3026 eradicates NPM-ALK+ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model

NPM-ALK⁺ T-cell anaplastic large-cell lymphoma (ALCL) is an aggressive type of cancer. Standard treatment of NPM-ALK⁺ ALCL is CHOP polychemotherapy. Although patients initially respond favorably to CHOP, resistance, relapse, and death frequently occur. Recently, selective targeting of ALK has emerged as an alternative therapeutic strategy. ASP3026 is a second-generation ALK inhibitor that can overcome crizotinib resistance in non-small cell lung cancer, and is currently being evaluated in clinical trials of patients with ALK⁺ solid tumors. However, NPM-ALK⁺ ALCL patients are not included in these trials. We studied the effects of ASP3026 on NPM-ALK⁺ ALCL cell lines in vitro and on systemic lymphoma growth in vivo. ASP3026 decreased the viability, proliferation, and colony formation, as well as induced apoptotic cell death of NPM-ALK⁺ ALCL cells. In addition, ASP3026 significantly reduced the proliferation of 293T cells transfected with NPM-ALK mutants that are resistant to crizotinib and downregulated tyrosine phosphorylation of these mutants. Moreover, ASP3026 abrogated systemic NPM-ALK⁺ ALCL growth in mice. Importantly, the survival of ASP3026-treated mice was superior to that of control and CHOP-treated mice. Our data suggest that ASP3026 is an effective treatment for NPM-ALK⁺ ALCL, and support the enrollment of patients with this lymphoma in the ongoing clinical trials.     

Absorption,distribution, metabolism and excretion of novel phosphodiesterase type 4 inhibitor ASP3258 in rats

The potent and selective phosphodiesterase 4 inhibitor ASP3258 is a novel therapeutic agent for asthma and chronic obstructive pulmonary disease (COPD). After a single oral administration to rats, ASP3258 is rapidly absorbed with a bioavailability of 106%. In situ absorption data indicated that ASP3258 is mainly absorbed in the small intestine. Tissue distribution data after oral administration of ¹⁴C‐ASP3258 showed rapid and extensive distribution to various tissues. Excluding the gastrointestinal tract, the tissues with the highest concentrations were liver, heart and plasma. Liquid chromatography‐nuclear magnetic resonance spectroscopy data revealed that O‐glucuronidation of the carboxylic acid moiety of ASP3258 (formation of an acyl glucuronide) plays a key role in metabolism. No indication was found that the acyl glucuronide reacted with proteins in plasma or tissues. When ¹⁴C‐ASP3258 was orally administered to intact rats, urinary and fecal excretion accounted for 1.3% and 100.6% of the administered radioactivity, respectively. After a single oral administration of ¹⁴C‐ASP3258 to bile‐cannulated rats, urinary and biliary excretion accounted for 0.7% and 93.8% of the administered radioactivity, respectively. These findings suggest that fecal excretion via bile plays an important role in the elimination of ASP3258‐derived radioactivity. In vitro metabolic profiles were relatively similar among the species examined, suggesting that our findings in rats may help us to understand pharmacokinetics, efficacy and safety profiles in humans and other species. Copyright © 2014 John Wiley & Sons, Ltd.